Advertisement
Screener

LEMAITRE VASCULAR, INC. (LMAT) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

3.3 / 5 stars · 78/120 Roast Me

LEMAITRE VASCULAR, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

LEMAITRE VASCULAR, INC. (LMAT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.70% for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-09.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2018-03-09

  • LEMAITRE VASCULAR, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2017 was 0.70%, a 46.15% decline from fiscal 2016.
  • LEMAITRE VASCULAR, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2016 was 1.30%, a 7.14% decline from fiscal 2015.
  • LEMAITRE VASCULAR, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2015 was 1.40%, a 22.22% decline from fiscal 2014.
  • LEMAITRE VASCULAR, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2014 was 1.80%, a 0.00% change from fiscal 2013.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month as first filedShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2017-12-310.70%
10-K · filed 2018-03-09
2017-09-301.30%
10-Q · filed 2017-11-03
2016-12-311.30%
10-K · filed 2018-03-09
2015-12-311.40%
10-K · filed 2018-03-09
2015-09-301.30%
10-Q · filed 2016-11-04
1.40%
10-Q · filed 2015-11-06
2014-12-311.80%
10-K · filed 2017-03-09
2014-09-301.40%
10-Q · filed 2016-11-04
1.80%
10-Q · filed 2014-11-06
2014-06-301.80%
10-Q · filed 2015-08-06
2013-12-311.80%
10-K · filed 2016-03-10
2013-09-301.80%
10-Q · filed 2014-11-06
2012-12-311.60%
10-K · filed 2015-03-18
2012-09-301.60%
10-Q · filed 2013-11-07
2011-12-311.10%
10-K · filed 2014-03-21
2011-09-301.10%
10-Q · filed 2012-11-09
2011-06-301.20%
10-Q · filed 2012-08-10
2010-12-310.00%
10-K · filed 2013-03-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
NovoCure Ltd (NVCR)$1.886B-11.87
Inspire Medical Systems, Inc. (INSP)United States$1.990B9.55
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)United States$1.535B-9.02
Alphatec Holdings, Inc. (ATEC)United States$1.531B-12.14
UFP TECHNOLOGIES INC (UFPT)United States$2.308B28.37
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)United States$1.234B-193.02
ARTIVION, INC. (AORT)United States$1.123B-345.09
IRADIMED CORP (IRMD)United States$1.089B52.92
TANDEM DIABETES CARE INC (TNDM)United States$1.059B-16.57
PROCEPT BioRobotics Corp (PRCT)United States$1.001B-11.77